Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 10, 2022
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
[ Wed, Aug 10th 2022
] - WOPRAI
Michael Ulz Maintained (XLO) at Buy with Decreased Target to $20 on, Aug 10th, 2022
Michael Ulz of Morgan Stanley, Maintained "Xilio Therapeutics, Inc." (XLO) at Buy with Decreased Target from $32 to $20 on, Aug 10th, 2022.
Michael, nor any peers, have made any analyst calls on XLO in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30